Home/Services/EU MDR Clinical Evaluation/Legacy Device CERs for the MDD-to-MDR Transition

Legacy Device CERs for the MDD-to-MDR Transition

Legacy Device CERs for the MDD-to-MDR Transition

Legacy device CER writing and MDD-to-MDR clinical evaluation support: evidence reassessment, gap analysis, historical data appraisal and document alignment.

The IMTS perspective

Evidence that stands up to scrutiny.

IMTS helps manufacturers reassess legacy device clinical evaluations for MDR expectations. The work examines what the existing evidence supports, which assumptions need revisiting, and what further analysis or data the transition package requires.

A previous CE certificate and a long sales history do not replace an appraisal of clinical evidence. Transition planning needs a device-specific gap assessment rather than a change of report headings.

Scope of support

What we can deliver.

How we work

A focused path from source evidence to final document.

01

Inventory the legacy package

Identify certificate and device scope, approved claims, historical evaluations, changes and available clinical records.

02

Reassess the evidence

Examine relevance, quality and applicability to the MDR evaluation questions and current state of the art.

03

Prepare the transition narrative

Document supported conclusions, unresolved gaps and the actions needed across connected records.

IMTS expertise

Authorship and review.

Legacy Device CERs for the MDD-to-MDR Transition

What changes in an MDD-to-MDR clinical evaluation

Start with the current device and claims, then assess the earlier evaluation against that scope. Historic investigations, published studies and postmarket records may remain relevant, but their applicability should be explained. An old summary table may omit the population, device configuration or endpoint detail needed to judge its contribution.

MDCG 2020-6 addresses clinical evidence for devices previously CE marked under the directives. Use it to frame the legacy evidence assessment alongside the applicable MDR provisions. It is not a waiver for every long-established product. Keep the original source records available so conclusions can be checked.

Legacy Device CERs for the MDD-to-MDR Transition

Transition deadlines are conditional

For eligible devices meeting the Article 120 conditions, extended transition periods run to 31 December 2027 for Class III and specified Class IIb implantables, and 31 December 2028 for other eligible categories. These are conditional dates, not a new application window. Device-specific eligibility needs a separate regulatory assessment.

The 2024 application, quality-system and notified body agreement conditions, continued directive compliance, significant-change restrictions and risk conditions matter. A CER writing engagement does not establish certificate validity or transition eligibility. Confirm those matters with your regulatory team before using a deadline as the project assumption.

Legacy Device CERs for the MDD-to-MDR Transition

Turn the evidence inventory into an actionable gap list

Classify each issue as a missing record, unclear analysis, unsupported claim or evidence-generation need. For instance, the absence of complaints is a different observation from a study demonstrating a claimed clinical benefit. Explain what each source can contribute without overstating its strength.

Send existing evaluations, literature logs, certificate scope, current IFU, change history, PMS/PMCF outputs and any notified body findings. Use CER remediation support for a finding-led response. If the report already meets the agreed baseline and simply needs a new evidence period, CER update services may be the more appropriate scope.

Primary regulatory sources

Check the applicable consolidated legislation and current guidance for the device. Guidance supports interpretation; it does not replace the MDR or a device-specific assessment.

Connected services and working guides

For the complete evaluation package, see IMTS Clinical Evaluation Report writing services.

For this transition workstream, discuss legacy device CER support. Our main CER service page explains the wider evaluation package.

Direct answers

Questions medical device teams ask.

Can we reuse clinical evidence from the MDD period?

Potentially. Reuse depends on relevance, quality and applicability to the current device, claims and evaluation questions. Previous inclusion in a CER does not establish sufficiency under MDR.

Does a 2027 or 2028 deadline mean every legacy device is eligible?

No. The extended periods apply only where the relevant transition conditions are met. Confirm the category, certification history and eligibility with your regulatory team.

Will a CER update resolve all transition gaps?

No. Some gaps require further clinical data, changes to claims or work elsewhere in the technical documentation. IMTS identifies writing and evidence dependencies in the agreed scope.

Start a conversation

Discuss this clinical evaluation workstream.

Share the current document set, evidence period and project question so we can agree a focused scope.

Book a Scoping Call